A 49-year-old man with syringomyelia and a Type
responses to the administration of growth hormonereleasing hormone (GHRH) and L-DOPA were normal, but his levels of IGF-I and IGFBP-3 did not increase after the administration of exogenous GH. Direct genomic DNA sequencing revealed neither a mutation nor deletion in this patient's GH receptor (GHR) gene, though one polymorphism was detected, indicating that his GHR gene was normal. This is the first reported case of an association of GHIS with syringomyelia and Chiari-I malformation.
Introduction
Growth hormone deficiency (GHD), which results in stunted growth, has been reported in patients with central nervous system (CNS) disorders.
Another cause of stunted growth is growth hormone insensitivity syndrome (GHIS), which develops in individuals who have either normal or elevated circulating levels of GH. These patients are unable to respond to endogenous as well as exogenous GH due to either an abnormality in their GH receptor (GHR), inability to transmit GH signals, or inactivity of insulin-like growth factor-I (IGF-I).
Abnormal craniofacial development has been reported in patients with GHD, GHIS, and Turner's syndrome (1-3), suggesting a role for GH and IGF-I in normal craniofacial development and implicating their absence or inactivity in the development of malformations. Birth trauma has been implicated as a cause of syringomyelia and pituitary GH insufficiency.
Syringomyelia, a disorder of the CNS, is frequently associated with a Chiari-I malformation, malformations of the skull or basilar impression, as well as other anomalies (4). Mukai et al (5) reported that patients who had experienced birth trauma also had syringomyelia that was associated not only with a Chiari-I malformation but also GHD, though another report suggested that isolated GHD need not be associated with birth trauma (6). Furthermore, Chiari-I malformations, basilar impression, and other anomalies were reported to be associated with GHD that was not linked to birth trauma (7). Therefore, birth trauma is not the only factor that has been implicated in the association of C hiari-I malformations and GHD with syringomyelia.
Weherein report a patient with syringomyelia that was associated with a Chiari-I malformation, short stature, and birth trauma. In spite of high circulating GH levels, the patient was unable to respond to exogenous or endogenous GH. Genomic DNA analysis revealed a polymorphism in the pa tient's GHR gene. Thus, this patient did not have GHD or a defect in the GHR gene, but rather had GHIS. This is the first reported association of syringomyelia and a Chiari-I malformation with GHIS.
Case Report
A 49-year old man with persistent fatigue was admitted to our hospital for examination. He was of short stature (145 cm), weighed 38 kg, and had a prominent forehead and high- pitched voice. He was born after 39 weeks of gestation, and his birth length and weight were 48 cm and 2,000 g, respectively; records showed that his parents were not biologically related. His father's height was 165 cm (-1.0 S.D.) and his mother's height was 155.5 cm (-0.5 S.D.). There was no family history of short stature or neurological diseases including syringomyelia and Chiari-I malformations, though his mother had delivered two stillborn siblings (one sister and one brother).
His own delivery was a breech delivery during which he experienced neonatal hypoxia. His growth has been retarded since early childhood and from kindergarten until graduation from high school, he was subjectively noted to have been the shortest student in his grade. School records indicated that the patient was 115 cm (-5.25 SD) in height at 13 years of age and 145 cm (-4.45 SD) in height at 18 years of age. The patient went through puberty while in high school and developed a progressively worsening limp and severe fatigue in junior high school that worsened thereafter. At the age of 33, he was diagnosed with syringomyelia that was associated with a Chiari-I malformation, and surgery to insert a fourth ventricular-subarachnoid shunt was performed. The progression of his gait disturbance was halted as a result of the operation, but he continued to experience severe fatigue, which seemed to worsen. Neurological examination showed muscle weakness in all extremities. Thermohypoesthesia and hypalgesia were prominent in the upper limbs and trunk, and pallhypesthesia in the extremities and trunk was also noted. Deep tendon reflexes were brisk, and Babinski and Chaddock signs were present. Laboratory data obtained at the time of admission were generally unremarkable (Table 1A ), but a low glucose level (47 mg/dl) was noted and was presumed to be a cause of the patient's fatigue. Baseline hormone levels at admission are summarized in Table IB . While the patient's serum GH level was higher than normal, his IGF-I and GH binding protein (GHBP) levels werebelow normal (Table IB) . There were no findings of liver dysfunction, malnutrition, or obesity, all of which are known to lower the IGF-I response to GH. were all within the normal range; thyroid and adrenal functions were also normal (Table   IB) .
The patient's GH response to L-DOPA administration was normal (Table 2A) as was his GH response to GHreleasing hormone loading (Table  2B) . Although his ACTH response was hyperactive, the responses of his other pituitary hormones were normal (Table 2B ). An IGF-I generation test, performed by injection of recombinant human GH (0.033 mg/kg), did not increase concentrations of serum IGF-I or I GFBP-3 on day 5 (Table  2C ).
The patient's bone age corresponded to that of an adult.
Magnetic resonance imaging (MRI) of the spine revealed C-2 to T-10 expansion of the syrinx and a Chiari-I malformation (Fig. 1A, B) . MRI of the head failed to reveal any obvious abnormalities in the hypothalamus or pituitary (Fig.  2) ; the size and location of the pituitary were also normal (Fig. 2) . Genomic DNA was extracted from the patient's peripheral leukocytes and the base sequence of the coding region (from exon 2 to exon 10) of the GHR gene was analyzed after PCR using primers reported by Kaji et al (8). An A174G polymorphism was found in exon 6, but no other mutations, abnormal splicings, or deletions were detected (Fig.  3 ).
Discussion
Syringomyelia is often associated with a Chiari-I malformation (9), the latter of which is considered to develop con- and Type I autosomal dominant osteopetrosis (12) have also been suggested to contribute to the development of syringomyelia in patients with a Chiari-I malformation. A genetic linkage has been reported in familial syringomyelia (13) while in another report of monozygotic triplets, one was found to have syringomyelia that was complicated by the presence of a Chiari-I malformation, while the other two had tonsillar ectopia (14). Mukai et al described patients of short stature with syringomyelia, some of whom also manifested a Chiari-I malformation, who also had GHD (5). They further noted that these patients also had a history of breech or forceps delivery. However, isolated GHD associated with syringomyelia and Chiari-I malformation, and GHD in patients with syringomyelia and other brain anomalies were reported to be unrelated to birth trauma (7). Therefore, it is unclear whether GHD develops in patients with syringomyelia and a Chiari-I malformation as a result of birth trauma or some other embryonic abnormality.
Remission in patients with a Chiari-I malformation is reported to have been associated with rapid bone growth, as determined by MRI (15), suggesting that discrepant growth of bone structures (skull and spine) and the CNS may be responsible for the development of a Chiari-I malformation, and that, on occasion, this condition may spontaneously resolve during periods of rapid growth. An association of GHIS with syringomyelia and a Chiari-I malformation has not been previously reported. GH and IGF-I play a critical role in growth and bone formation, including craniofacial and basilar construction; abnormalities in craniofacial development were noted in patients with GHD, GHIS, and Turner syndrome (1-3). Since the effect of IGF-I on growth is identical to that seen with GH, it is suggested that the defective GHR response that is observed in patients with GHIS may contribute to the development of basicranial malformations and thereby may play a role in the pathogenes is of syringomyelia and Chiari-I malformations.
The present patient displayed a short stature and hypogly- . Furthermore, the levels of IGFBP-3 mRNA in the cultured skin fibroblasts from these patients did not increase in response to GH. These investigators examined GH-induced activation of Janus thyrosine ki nase-signal transducers of transcription (JAK-STAT) signaling in these cells and mentioned that GHIS phenotype is probably caused by defects in GH signaling pathway affecting mitogen-activated protein kinase (MAPK). Since the present patient had normal GH secretion, an absence of an increase in IGF-I or IGFBP-3 to GH administration, and no mutation in the coding region of the GHR gene, a postreceptor dysfunction in JAK-STAT signaling may play a role in the expression of the GHIS phenotype. It is also possible that GHIS in this patient was due to a defect in the GH gene, since we did not evaluate the biochemical activity of endogenous GH. However, administration of bioactive, human recombinant GH to evaluate his GHR response, failed to induce IGF-1 secretion. The lack of IGF-I generation is a reflection of GHR insensitivity, though GH inactivity could concomitantly exist. Inactivity of the IGF-I gene also causes GHIS, so an abnormality in IGF-I activity may also be a contributing factor in the development of this condition. The foregoing notwithstanding, our patient's GHIS could not have been caused by defects in IGF-I alone since exogenous GH administration revealed a defective GHR response. Based on the patient's laboratory findings, the reduced GHR response to GH was not due to liver dysfunction, malnutrition, or obesity. A clinical association between syringomyelia, Chiari-I malformation, and GHIS (Laron syndrome) has not been previously reported. Our patient's GHR gene was found to be normal except for the presence of one polymorphism; his pituitary GH secretion was normal, and his IGF-I levels did not increase after administration of exogenous GH. We conclude that this patient represented a rare case of GHIS that was complicated by the presence of syringomyelia and a Chiari-I malformation.
